NEW YORK--(BUSINESS WIRE)--May 8, 2006--OMRIX Biopharmaceuticals, Inc. (NASDAQ: OMRI - News) announced today that the underwriters have exercised an over-allotment option to purchase an additional 515,625 shares of its common stock in connection with its initial public offering that priced on April 20, 2006. Including the over-allotment shares being purchased, the offering will total 3,953,125 shares at a public offering price of $10.00 per share, resulting in expected net proceeds to the Company of approximately $35 million (after payment of underwriting discounts and including estimated offering expenses).
